Related Experiment Video

Updated: Feb 7, 2026

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

2.1K

Preoperative ondansetron lozenge for prevention of postoperative nausea and vomiting in pediatrics undergoing squint

Saad A Moharam1, Mohammed S Elsharkawy2, Shaimaa W Zahra2

  • 1Department of Anesthesiology, Surgical Intensive Care and Pain Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt - saad.moharam@med.tanta.edu.eg.

Minerva Anestesiologica
|February 5, 2026
PubMed

Insights

Preoperative ondansetron lozenges significantly reduced postoperative nausea and vomiting (PONV) in pediatric squint surgery patients. This intervention also decreased PONV severity and improved parental satisfaction.

Area of Science:

  • Anesthesiology
  • Pediatric Surgery
  • Pharmacology

Background:

  • Postoperative nausea and vomiting (PONV) is a significant challenge in pediatric squint surgery.
  • PONV can lead to serious complications in children.
  • Effective prophylactic strategies are needed to manage PONV in this population.

Purpose of the Study:

  • To evaluate the efficacy of preoperative ondansetron lozenges in preventing PONV in pediatric patients undergoing squint surgery.
  • To compare PONV incidence and severity between ondansetron and control groups.

Main Methods:

  • A randomized controlled trial involving 80 pediatric patients (aged 4-15 years) undergoing squint surgery.
  • Patients were assigned to receive either a 4 mg ondansetron lozenge preoperatively or a control treatment.
  • PONV incidence, severity, time to emesis, oculocardiac reflex, and parental satisfaction were assessed.

Main Results:

  • The ondansetron group showed significantly lower PONV incidence (22.5% vs. 52.5%, P=0.006).
  • Ondansetron reduced PONV severity across all measured intervals and prolonged time to emesis (P=0.005).
  • Incidence of the oculocardiac reflex was lower (12.5% vs. 37.5%, P=0.018), and parental satisfaction was higher in the ondansetron group (P=0.004).

Conclusions:

  • Preoperative ondansetron lozenges are effective in reducing PONV incidence and severity in pediatric squint surgery.
  • This intervention also mitigates complications like the oculocardiac reflex.
  • Ondansetron lozenges represent a promising prophylactic strategy for PONV in pediatric ophthalmic surgery.
Abstract

More Related Videos

Author Spotlight: Advancements and Challenges in Surgical Treatments for Postamputation Pain03:26

Author Spotlight: Advancements and Challenges in Surgical Treatments for Postamputation Pain

Published on: March 8, 2024

3.6K
Author Spotlight: Regenerative Peripheral Nerve Interface (RPNI) Surgery in Postamputation Pain Management03:53

Author Spotlight: Regenerative Peripheral Nerve Interface (RPNI) Surgery in Postamputation Pain Management

Published on: March 15, 2024

2.9K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
790
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
681
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
890
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
627
Pathophysiology of Vomiting01:22

Pathophysiology of Vomiting

Vomiting is a complex physiological response to expel harmful or irritating substances from the body. It's a defensive mechanism triggered by stimuli like poisons, microbial toxins, cytotoxic drugs, and mechanical abdominal distension. The process is centrally coordinated by the vomiting (or emetic) center located in the medulla of the brainstem. This area, rich in muscarinic M1, histamine H1, neurokinin 1 (NK1), and serotonin 5-HT3 receptors, coordinates the act of vomiting through...
3.1K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.0K